Our Pricing

Wegovy Dosage Chart: Complete UK Dose Escalation Guide

Published on: June 03, 2026

The wegovy dosage chart is essential for understanding how this semaglutide injection works through a gradual dose escalation protocol over 16 weeks. Wegovy starts at 0.25mg weekly and increases systematically to the maintenance dose of 2.4mg, a schedule designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes [1]. At Cured Pharmacy, we provide the complete wegovy dosage chart alongside clinical support from UK-registered prescribers, with transparent pricing from £69.00 and free consultations under three minutes.

Understanding the Wegovy Dosage Chart Escalation Schedule

The wegovy dosage chart follows a structured five-month escalation protocol validated in the STEP clinical trial programme [1]. Each dose increase occurs every four weeks, allowing your body to adapt to higher semaglutide concentrations whilst reducing the risk of nausea, vomiting, and other gastrointestinal effects. This gradual approach differs significantly from fixed-dose medications and represents a core principle of GLP-1 receptor agonist therapy.

Week 1-4 begins with 0.25mg weekly, the lowest therapeutic dose that initiates GLP-1 receptor activation without overwhelming your digestive system. Weeks 5-8 progress to 0.5mg, where many patients begin noticing appetite suppression and early weight loss [2]. The wegovy dosage chart then advances to 1mg (weeks 9-12), 1.7mg (weeks 13-16), and finally 2.4mg from week 17 onwards as your maintenance dose. Each pen delivers four weeks of treatment at a single dose strength, eliminating the need for dose adjustments between pens.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) emphasises that adherence to the wegovy dosage chart directly correlates with treatment success. Patients who skip dose escalations or attempt to accelerate the schedule experience significantly higher discontinuation rates due to side effects [3]. The chart exists not merely as a guideline but as a clinically optimised pathway developed through extensive phase 3 trials involving over 4,500 participants.

Wegovy Dosage Chart: Weekly Injection Strengths Explained

Each strength on the wegovy dosage chart corresponds to a specific pen colour and label, reducing administration errors. The 0.25mg pen (red label) contains four doses of 0.25mg each, whilst the 0.5mg pen (orange) similarly provides four weekly injections. As you progress through the wegovy dosage chart, the 1mg pen (yellow), 1.7mg pen (green), and 2.4mg pen (blue) each contain four pre-filled doses at their respective strengths.

The 2.4mg maintenance dose represents the therapeutic target demonstrated in STEP trials to produce an average 14.9% body weight reduction over 68 weeks [1]. This dose provides optimal GLP-1 receptor saturation for appetite regulation, delayed gastric emptying, and enhanced insulin secretion. Some patients achieve significant weight loss at lower doses on the wegovy dosage chart, but clinical evidence consistently shows superior outcomes at the full 2.4mg maintenance level.

Importantly, the wegovy dosage chart allows for dose flexibility under prescriber guidance. If you experience persistent side effects at a higher dose, your clinician may recommend remaining at the previous strength for an additional four weeks before attempting escalation again. This individualised approach maintains the safety profile whilst working towards the evidence-based maintenance dose.

Wegovy Dosage Chart Timing and Administration

The wegovy dosage chart specifies once-weekly subcutaneous injection, administered on the same day each week regardless of dose strength. You can inject into your abdomen, thigh, or upper arm, rotating sites to prevent lipodystrophy. Each pen delivers a single dose automatically when the injection button is pressed and held for approximately six seconds, with an audible click confirming completion.

Timing flexibility exists within the wegovy dosage chart framework—you may take your injection at any time of day, with or without food. If you miss a scheduled dose and the next dose is more than two days away, take the missed dose as soon as you remember. If fewer than two days remain, skip the missed dose and resume your normal schedule. Never double doses to compensate for missed injections, as this violates the wegovy dosage chart safety protocol and increases side effect risk [4].

Wegovy Dosage Chart Compared to Other Weight Loss Treatments

The wegovy dosage chart's gradual escalation distinguishes it from other weight loss medications available in the UK. Saxenda (liraglutide) uses a different GLP-1 agonist with daily injections escalating from 0.6mg to 3mg over five weeks, whilst Mounjaro (tirzepatide) combines GLP-1 and GIP receptor activation with its own dose titration from 2.5mg to 15mg. The wegovy dosage chart's once-weekly schedule offers superior adherence compared to daily injection regimens [2].

Orlistat and Xenical represent non-injection alternatives but work through fat absorption inhibition rather than appetite regulation, producing average weight loss of 3-5% compared to Wegovy's 14.9% in clinical trials [1]. The wegovy dosage chart's pharmacological approach addresses multiple metabolic pathways simultaneously—reducing hunger, slowing gastric emptying, and improving glycaemic control—explaining its superior efficacy profile.

At Cured Pharmacy, we provide the complete wegovy dosage chart alongside alternative treatments, allowing our UK-registered prescribers to recommend the most appropriate option based on your medical history, weight loss goals, and tolerance for injection therapy. All treatments require online clinical assessment, with transparent pricing from £69.00 for Wegovy showing the cost before you begin consultation.

Clinical Evidence Supporting the Wegovy Dosage Chart Protocol

The wegovy dosage chart derives from the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme, which established both efficacy and safety across diverse patient populations [1]. STEP 1, the pivotal 68-week trial, demonstrated that 86.4% of participants achieved at least 5% weight loss following the standard wegovy dosage chart, with 69.1% achieving 10% or greater reduction and 50.5% reaching 15% or more body weight loss.

Cardiovascular outcomes data further validates the wegovy dosage chart approach. The SELECT trial showed semaglutide 2.4mg weekly reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease, independent of weight loss magnitude [5]. This cardioprotective effect emerges specifically at the maintenance dose level specified in the wegovy dosage chart, not at lower escalation doses.

Safety monitoring throughout the STEP programme confirmed that the wegovy dosage chart's gradual escalation minimises discontinuation due to adverse effects. Gastrointestinal side effects—primarily nausea, diarrhoea, and constipation—occurred in 44% of participants but were predominantly mild to moderate and decreased over time as patients progressed through the dose escalation schedule [3]. Serious adverse events occurred at similar rates to placebo groups, confirming the wegovy dosage chart's safety when administered under medical supervision.

Long-Term Weight Maintenance on the Wegovy Dosage Chart

The STEP 4 withdrawal trial examined what happens when patients discontinue the wegovy dosage chart after reaching maintenance dose. Participants who stopped treatment regained approximately two-thirds of their lost weight over 48 weeks, whilst those continuing the 2.4mg maintenance dose sustained their weight loss [6]. This demonstrates that Wegovy functions as a chronic disease treatment rather than a short-term intervention.

Patients remaining on the wegovy dosage chart maintenance dose for two years in extension studies maintained average weight loss of 15.2%, with continued improvements in waist circumference, blood pressure, and lipid profiles [7]. The once-weekly injection schedule at 2.4mg represents the evidence-based protocol for sustained weight management, requiring ongoing clinical supervision and lifestyle modification support.

Wegovy Dosage Chart: Managing Side Effects During Escalation

Understanding potential side effects at each stage of the wegovy dosage chart helps you prepare and manage symptoms effectively. Nausea represents the most common adverse effect, typically peaking 1-3 days after injection and diminishing as your body adapts to each new dose level. Eating smaller, more frequent meals and avoiding high-fat foods can significantly reduce gastrointestinal discomfort during dose escalation [4].

The wegovy dosage chart's four-week intervals between dose increases allow adequate time for tolerance development. If you experience persistent vomiting, severe abdominal pain, or signs of pancreatitis (severe upper abdominal pain radiating to your back), contact your prescriber immediately. These symptoms may necessitate dose reduction or treatment discontinuation, decisions that must be made under medical supervision rather than through self-adjustment.

Constipation affects approximately 24% of patients progressing through the wegovy dosage chart and responds well to increased fluid intake, dietary fibre, and physical activity [3]. Our clinical team at Cured Pharmacy provides ongoing support throughout your dose escalation journey, with free messaging access to UK-registered prescribers who can adjust your treatment plan if side effects become problematic. We ensure you understand each stage of the wegovy dosage chart before progressing to higher doses.

Accessing the Wegovy Dosage Chart Through Cured Pharmacy

Obtaining Wegovy through Cured Pharmacy begins with a free online consultation taking under three minutes, where our UK-registered prescribers assess your suitability for the wegovy dosage chart protocol. We evaluate your BMI, medical history, current medications, and weight loss goals to determine if Wegovy represents the most appropriate treatment option. All prescription decisions comply with MHRA guidelines and NICE recommendations for obesity management.

Our transparent pricing shows £69.00 for Wegovy before you begin assessment, with £20 off your first order using code Weightlossnew, bringing your initial cost to £69.00. This represents the cheapest UK price for genuine, UK-licensed Wegovy, dispensed by our GPhC-registered pharmacy (9012511) with 100% discreet packaging and next-day delivery options. We provide the complete wegovy dosage chart documentation with your first prescription, ensuring you understand the entire escalation schedule from 0.25mg through to 2.4mg maintenance.

Ongoing prescriptions follow the wegovy dosage chart automatically, with our clinical team reviewing your progress at each dose transition. We coordinate prescription renewals to align with your escalation schedule, eliminating gaps in treatment that could compromise efficacy. Our superintendent pharmacist Tarun Kumar oversees all dispensing, ensuring every pen meets UK regulatory standards and arrives with proper storage instructions and administration guidance. Contact our team on (+44) 116 4646009 for personalised advice about starting the wegovy dosage chart protocol.

Wegovy Dosage Chart: What to Expect in Your First Month

Your first month on the wegovy dosage chart uses the 0.25mg starter dose, which initiates GLP-1 receptor activation whilst minimising side effects. Many patients notice reduced appetite and smaller portion satisfaction within the first week, though significant weight loss typically emerges as you progress to higher doses. The initial 0.25mg phase establishes treatment tolerance and confirms you can manage subcutaneous injections comfortably.

We recommend tracking your weight weekly, monitoring for side effects, and maintaining a food diary during your first month on the wegovy dosage chart. This documentation helps your prescriber assess treatment response and determine readiness for dose escalation to 0.5mg in week five. Remember that the wegovy dosage chart represents a 16-week journey to maintenance dose—patience during the escalation phase correlates directly with long-term treatment success and tolerability.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 13 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 13 August 2026]
3. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 13 August 2026]
4. Novo Nordisk. (2023). Wegovy (semaglutide) injection 2.4 mg: Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 13 August 2026]
5. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. [accessed 13 August 2026]
6. Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., et al. (2021). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA, 327(2), 138-150. [accessed 13 August 2026]
7. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.